for pigmentation
98%+ · 10mg · Lyophilized
Bulk discount
3+ pcs
€42.65
−5%
5+ pcs
€40.41
−10%
10+ pcs
€38.16
−15%
Discount is applied automatically at checkout.
🎉 One free — saved €44.9
Preview: offer goes live at launch.
The catalog is not yet accepting orders. Join the list.
In Stock - Ships within 24 hours
Free shipping over €49
This product is sold strictly for in lab conditions (in vitro) research purposes. Not approved for human consumption.
Verified above 98%
98%+ verified — most batches reach 99%+
Included
Independent analysis from accredited laboratories
EU Shipping
3-7 days across the EU (Bulgaria — 1-2 days)
Secure Payment
Cash on delivery
Melanotan I
Melanocortin Receptor Agonist | Afamelanotide
In short
Selective α-MSH analog studied for activating MC1R receptors and inducing melanogenesis in dermal models.
Best sellers
Education
Related resources
Ready-to-use starter kit
Melanotan I (afamelanotide) is a synthetic peptide that mimics the body's natural alpha-melanocyte-stimulating hormone. At the molecular level, it selectively binds to MC1 receptors, thereby stimulating the production of the pigment melanin. In laboratory settings (in vitro and in animal models), researchers are studying its photoprotective properties and its ability to induce skin darkening. Although there is an FDA-approved implant containing this active ingredient (SCENESSE®) for specific medical conditions, this injectable product is intended solely for scientific research and is not a medication for human use.
Research reagent for laboratory use only. Not a medicine. For medical questions, consult a physician.
Scientific review
Written by
Калина Тодорова
Magister Pharmaciae, MSc Pharmacy
Reviewed by
Борис Маринов
MSc Biochemistry & Molecular Biology
Reviewed on
Melanotan I (afamelanotide) is a synthetic analog of α-melanocyte stimulating hormone that selectively targets MC1 receptors to stimulate melanin production. While an FDA-approved implant version (SCENESSE®) exists for rare medical conditions, research-grade injectable Melanotan I is studied for its photoprotective and tanning effects through regular subcutaneous administration.
MC1R-selective melanogenesis activation FDA-approved for erythropoietic protoporphyria (Scenesse 2014) UV-independent photoprotection No CNS confounders of pan-melanocortin agonists
Subcutaneous injection delivers Melanotan I directly into systemic circulation with 100% bioavailability. 30-minute half-life requires multiple daily injections for sustained MC1R activation and melanin production.
Stimulates melanin production allowing deeper, longer-lasting tan with reduced UV exposure requirements
Increased melanin density provides natural protection against UV damage and reduces sunburn susceptibility
Promotes uniform melanin distribution reducing patchy tanning and providing consistent skin tone
Dosing
The typical regimens you'll see in the published research - for reference when planning in vitro or in vivo experiments. Not medical advice.
Disclaimer
These are regimens discussed in the research literature, not medical advice. Consult a healthcare provider before use.
Timing
Morning and evening injections, 6-8 hours apart
[Calculator]
Change water and dose · results update in real time
from product
Visual indicator
Pull to mark 5.0
5.0marks
Standard insulin syringe 1 ml (100 marks)
Concentration
5.00mg/ml
Dose volume
0.050ml
U-100 units
5.0units
Doses per vial
40doses
Recommended needle
29G–30G / 1 ml insulin
Small volume — draw slowly; 30G works for finer precision
Cycle planner: vials for 12 weeks, cost, schedule
Opens full calculator
Results are reference values - for in vitro work. Verify against the published literature for the specific peptide.
[Step by step]
6 steps from a sealed vial to the injection. Plain language.
Peptide vial (10 mg), bacteriostatic water vial, 1 larger syringe (3-5 ml) for drawing water and 1 insulin (1 ml) for doses. Alcohol swabs for sanitizing the caps.
Wash your hands before starting.
Wipe the rubber cap of the water vial with an alcohol swab. Insert the needle, invert the vial and draw exactly 2 ml. Get the exact volume from the calculator.
Larger syringe = smaller error in volume.
Wipe the peptide vial cap. Tilt the vial 45° and release the water SLOWLY down the inner wall. Peptides are fragile — a direct stream onto the powder denatures them.
SLOWLY · DOWN THE WALL · NOT ONTO THE POWDER.
Hold the vial between both palms and swirl slowly. DO NOT shake or flip sharply — peptides break down under mechanical stress.
DON'T SHAKE. Like tea — not like a cocktail.
The powder should fully dissolve. The solution is clear, no visible particles. If cloudy or with sediment — discard (wrong water or bad batch).
Clear = OK. Cloudy = discard.
With the insulin syringe draw the exact marks from the calculator. Swab the skin (abdomen 5 cm around the navel, thigh, or buttock), pinch a fold, insert at 45-90° and inject slowly.
Rotate sites every injection to avoid lipohypertrophy.
Schedule
Morning and evening injections, 6-8 hours apart
Allow vial to reach room temperature (15-20 minutes)
Clean vial top with alcohol swab and allow to dry
Calculate required bacteriostatic water volume using the calculator below
Draw calculated volume of bacteriostatic water into syringe
Inject water slowly down the inside wall of the vial (never directly onto powder)
Gently swirl until powder completely dissolves (never shake)
Solution should be clear - discard if cloudy or contains particles
Store reconstituted solution in refrigerator at 2-8°C
Research peptide - not approved for human consumption, sold for research purposes only
Start with lower doses to assess individual tolerance and response
Monitor moles and skin changes - perform regular self-examinations
Use proper sterile injection technique to prevent infections
Maintain UV protection despite enhanced tanning - still risk of overexposure
Compatibility
The pairings below come from research literature and established biohacker stacking patterns. Click a card for the full reasoning - when the partner is in our catalog you'll see a direct order link too.
This is a literature overview, not medical advice. Pairs not listed are not proven safe - they simply lack enough published data.
References
Links to peer-reviewed publications on PubMed, cited in the peptide's scientific profile.
Safety Profile Assessment (2006)
Humans | 147 subjects | Multiple doses | Minimal adverse events
Comprehensive safety evaluation showing excellent tolerability profile with transient nausea and flushing as primary side effects. No serious adverse events reported.
View the studyMT-I Photoprotection Study (2004)
Humans | 0.08-0.16 mg/kg | 28 days | Enhanced tanning, reduced UV damage
Clinical study demonstrating Melanotan I ability to induce protective tanning with reduced UV exposure requirements. Subjects showed enhanced melanin production and decreased sunburn susceptibility.
View the studyTanning Efficacy Comparison (2003)
Humans | vs placebo | UV-free tanning assessment
Study demonstrating Melanotan I ability to produce visible tanning without UV exposure, though enhanced effects observed when combined with minimal UV exposure.
View the studyMelanocortin Receptor Binding Study (1997)
In vitro | Multiple concentrations | MC1R selectivity analysis
Comprehensive analysis showing Melanotan I 1000-fold higher binding affinity to MC1R compared to natural α-MSH, with minimal binding to other melanocortin receptors.
View the studyPharmacokinetics of Injectable MT-I (1997)
Humans | Subcutaneous injection | 30-minute half-life | 100% bioavailability
Pharmacokinetic study establishing subcutaneous bioavailability and rapid clearance profile of injectable Melanotan I, requiring multiple daily administrations for sustained effects.
View the study
for longevity
for sexual health
No reviews yet. Be the first.
Share your experience with this peptide. We publish after a short moderation.
